127 related articles for article (PubMed ID: 8903498)
1. Hyperthermic isolated limb perfusion with cisplatin in four patients with sarcomas of soft tissue and bone.
van Ginkel RJ; Schraffordt Koops H; de Vries EG; Molenaar WM; Uges DR; Hoekstra HJ
Eur J Surg Oncol; 1996 Oct; 22(5):528-31. PubMed ID: 8903498
[TBL] [Abstract][Full Text] [Related]
2. Hyperthermic isolated limb perfusion in locally advanced limb soft tissue sarcoma: A 24-year single-centre experience.
Rastrelli M; Campana LG; Valpione S; Tropea S; Zanon A; Rossi CR
Int J Hyperthermia; 2016; 32(2):165-72. PubMed ID: 26608883
[TBL] [Abstract][Full Text] [Related]
3. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?
Olieman AF; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
Arch Orthop Trauma Surg; 1998; 118(1-2):70-4. PubMed ID: 9833110
[TBL] [Abstract][Full Text] [Related]
4. Hyperthermic isolation limb perfusion (HILP) in the management of extremity melanoma and sarcoma with particular reference to the dosage, pharmacokinetics, and toxicity of cisplatin.
Fletcher WS; Woltering EA; Moseley HS; Bos G; Lebredo L; Brown D; Small K
Cancer Treat Res; 1993; 62():241-4. PubMed ID: 8096739
[No Abstract] [Full Text] [Related]
5. [Relations of chemotherapy-induced tumor necrosis to plasma platin concentration and primary tumor temperature in patients with osteosarcoma in the lower extremities treated by hyperthermic isolation limb perfusion with cisplatin].
Fan S; Yang D; Tao H; Ye Z; He R
Zhonghua Wai Ke Za Zhi; 2000 May; 38(5):336-9. PubMed ID: 11832050
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermic isolated limb perfusion for extremity sarcomas.
Kim CJ; Puleo C; Letson GD; Reintgen D
Cancer Control; 2001; 8(3):269-73. PubMed ID: 11378653
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic isolated limb perfusion in the management of extremity sarcoma.
Hoekstra HJ; van Ginkel RJ
Curr Opin Oncol; 2003 Jul; 15(4):300-3. PubMed ID: 12874508
[TBL] [Abstract][Full Text] [Related]
8. Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study.
Lasithiotakis K; Economou G; Gogas H; Ioannou C; Perisynakis K; Filis D; Kastana O; Bafaloukos D; Decatris M; Catodritis N; Frangia K; Papadakis G; Magarakis M; Tsoutsos D; Chrysos E; Chalkiadakis G; Zoras O
Oncol Rep; 2010 Apr; 23(4):1077-83. PubMed ID: 20204294
[TBL] [Abstract][Full Text] [Related]
9. Hyperthermic isolated perfusion using cisplatin for treatment of the extremities.
Takeyama S; Tateishi A; Higaki S; Yamanashi M
Cancer Treat Res; 1993; 62():235-40. PubMed ID: 8096738
[No Abstract] [Full Text] [Related]
10. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
[TBL] [Abstract][Full Text] [Related]
11. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations.
Issakov J; Merimsky O; Gutman M; Kollender Y; Lev-Chelouche D; Abu-Abid S; Lifschitz-Mercer B; Inbar M; Klausner JM; Meller I
Ann Surg Oncol; 2000 Mar; 7(2):155-9. PubMed ID: 10761796
[TBL] [Abstract][Full Text] [Related]
12. Hyperthermic isolated regional perfusion for the treatment of osteosarcoma in the lower extremity.
Nakano H; Tateishi A; Miki H; Imamura T; Cho S; Abe S; Matsushita T
Am J Surg; 1999 Jul; 178(1):27-32. PubMed ID: 10456698
[TBL] [Abstract][Full Text] [Related]
13. Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
Komdeur R; Plaat BE; Hoekstra HJ; Molenaar WM; Hollema H; van den Berg E; Mastik MF; van der Graaf WT
Cancer; 2001 May; 91(10):1940-8. PubMed ID: 11346877
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma.
van Ginkel RJ; Hoekstra HJ; Pruim J; Nieweg OE; Molenaar WM; Paans AM; Willemsen AT; Vaalburg W; Koops HS
J Nucl Med; 1996 Jun; 37(6):984-90. PubMed ID: 8683328
[TBL] [Abstract][Full Text] [Related]
15. [Isolation perfusion chemotherapy using cisplatin in malignant tumors of the extremities].
Takeyama S; Tateishi A; Miki H; Yamanashi M; Hayashi I; Higaki S; Kozima T; Iizima T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-3):1764-70. PubMed ID: 2543321
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the drug resistance-associated protein metallothionein does not correlate with response of sarcomas to isolated limb perfusion treatment.
Grabellus F; Sheu SY; Tötsch M; Lehmann N; Kaiser GM; Jasani B; Taeger G; Schmid KW
J Surg Oncol; 2010 May; 101(6):465-70. PubMed ID: 20401916
[TBL] [Abstract][Full Text] [Related]
17. The role of hyperthermic perfusion in the treatment of tumors of the extremities.
Di Filippo F; Carlini S; Cavaliere F; Giannarelli D; Cavallero L; Moscarelli F; Aloe L; Cavaliere R
Adv Exp Med Biol; 1990; 267():223-34. PubMed ID: 2088040
[No Abstract] [Full Text] [Related]
18. [Results of isolated hyperthermic extremity perfusion in soft tissue sarcomas within the scope of a multimodality treatment concept].
Schwarzbach M; Lehnert T; Willeke F; Hinz U; Herfarth C
Chirurg; 1996 Dec; 67(12):1237-43. PubMed ID: 9081786
[TBL] [Abstract][Full Text] [Related]
19. Neurotoxicity of isolated limb perfusion with tumor necrosis factor.
Drory VE; Lev D; Groozman GB; Gutmann M; Klausner JM
J Neurol Sci; 1998 Jun; 158(1):1-4. PubMed ID: 9667770
[TBL] [Abstract][Full Text] [Related]
20. Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment.
Hoekstra HJ; Schraffordt Koops H; de Vries LG; van Weerden TW; Oldhoff J
Cancer; 1993 Aug; 72(4):1224-9. PubMed ID: 8393368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
